Replies to post #124569 on Cytodyn Inc (CYDY)

[GreenBioAnalyst]

That's only $24. With potential approval of Leromlimab in all sequelae, the global peak sales will be closed to $5b peak sales! Gilead is forecasting $1b to $3b for Remde for that for Moderate CV19 only. Very limited use.

Btw, as for my model, that's per qtr here in the U.S. $600m with 25% qtrly compounded growth rate usage or in sales.

[3X Charm]

You are kidding, right? Just in case : Take estimated net earnings, multiply by 24 and divide by number of shares.